Aquestive Therapeutics (AQST) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prothena (PRTA) has outperformed Aquestive Therapeutics (AQST) over the past year, losing 21.6% versus a loss of 39.5%. Over five years, AQST leads with a -45.7% price change compared with -83.3% for PRTA. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $422.1 million), about 1.0 times the size.
Aquestive Therapeutics converts more of its revenue into profit, with a net margin of -188.1% versus -2520.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | PRTA |
|---|---|---|
| Share price | $3.46 | $8.22 |
| Market cap | $434.88M | $422.10M |
| 1-day change | -6.61% | -2.14% |
| YTD return | -46.44% | -13.93% |
| 1-year return | -39.51% | -21.56% |
| 5-year return | -45.68% | -83.28% |
| EPS (TTM) | $-0.65 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.55M | $9.68M |
| Revenue growth (YoY) | -22.61% | -92.83% |
| Net income (latest FY) | $-83.78M | $-244.09M |
| Gross margin | 58.35% | — |
| Operating margin | -159.50% | -2216.44% |
| Net margin | -188.09% | -2520.57% |
| 52-week high | $6.74 | $11.80 |
| 52-week low | $2.93 | $7.70 |
| Distance from 52-week high | -48.63% | -30.34% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +169.65% | +160.34% |
| Average volume | 2.41M | 487.91K |
| Shares outstanding | 125.69M | 51.35M |
| Employees | 147 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRTA has outperformed AQST by 17.9 percentage points over the past year.
- Aquestive Therapeutics is more profitable, keeping -188.1 cents of every revenue dollar as net income versus -2520.6 cents for Prothena.
- Aquestive Therapeutics grew revenue faster in its latest fiscal year (-22.61% vs -92.83%).
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
AQST vs PRTA FAQ
Which is bigger, Aquestive Therapeutics or Prothena?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $422.10M for Prothena (PRTA).
Which stock has performed better over the past year, AQST or PRTA?
PRTA returned -21.56% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.